BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile


Janssen Research & Development 

3210 Merryfield Row

San Diego  California  92121  U.S.A.
Phone: 858-450-2000 Fax: n/a


At Janssen Research & Development, LLC, we are united and energized by one mission – to discover and develop innovative medicines that ease patients' suffering, and solve the most important unmet medical needs of our time.

As one of the Janssen Pharmaceutical Companies, our strategy is to identify the biggest unmet medical needs and match them with the best science, internal or external, to find solutions for patients worldwide. We leverage our world-class discovery and development expertise, and operational excellence, to bring innovative, effective treatments in five therapeutic areas:

• cardiovascular and metabolism,
• immunology,
• infectious diseases and vaccines,
• neuroscience, and
• oncology.

We think of the world as our laboratory and we look for innovation wherever it exists. This drives our relentless search for the best science, and our pursuit of collaborations and partnerships.

We believe there are no limits to what science can do. And we never lose sight of those who rely most on our discoveries.


Janssen Labs is part of Johnson & Johnson’s external research and development engine and provides a capital-efficient, resource-rich environment where independent emerging companies can progress their research.
The 30,000 square foot flagship facility opened in early 2012 in San Diego at Janssen’s West Coast Research Center and currently hosts 30 emerging life science companies. Janssen Labs offers singular bench tops, modular wet lab units and office space on a short-term basis, allowing companies to pay only for the space they need, with an option to quickly expand when they have the resources to do so. Janssen Labs is an open innovation model, and the agreement for space does not grant Janssen any stake in the companies, nor will the companies have a guaranteed future affiliation with Janssen; but the models is designed to initiate a dialogue early and foster long term relationships with innovators in healthcare.

 Key Statistics

Ownership: Private

Web Site: Janssen Research & Development


 Company News
JDRF Supports Janssen Research & Developments Disease Interception Approach To Prevent The Clinical Onset Of Type 1 Diabetes 2/12/2015 6:46:30 AM
Janssen Research & Development Sets A Course To Intercept Type 1 Diabetes Together With JDRF 2/12/2015 6:45:11 AM
Janssen Research & Development Release: IMBRUVICA (ibrutinib) Long-term Follow-up Data In Patients Living With Relapsed/Refractory Mantle Cell Lymphoma Show Almost Half Alive At Two Years 12/9/2014 7:16:52 AM
Janssen Research & Development Release: IMBRUVICA (ibrutinib) Shows Sustained Progression-Free Survival In Patients With High-Risk Chronic Lymphocytic Leukemia With Genetic Mutation 12/9/2014 7:14:26 AM
Janssen Research & Development Submits New Drug Application For YONDELIS (trabectedin) To U.S. FDA For The Treatment Of Patients With Advanced Soft Tissue Sarcoma 11/25/2014 9:00:45 AM
Janssen Research & Development To Demonstrate Breadth Of Oncology Portfolio With 42 Clinical Data Presentations At The 2014 American Society of Hematology Annual Meeting 11/6/2014 10:28:30 AM
Janssen Research & Development Collaborates For Continued Evaluation Of Multidrug-Resistant Tuberculosis Treatment Regimens With SIRTURO® (bedaquiline) 11/6/2014 7:54:10 AM
Janssen Research & Development Release: IMBRUVICA® (ibrutinib) Supplemental New Drug Application Submitted To The U.S. FDA For Waldenstrom's Macroglobulinemia 10/20/2014 7:23:33 AM
Bristol-Myers Squibb Company (BMY), Pharmacyclics, Inc. (PCYC), And Janssen Research & Development Announce Clinical Collaboration To Evaluate OPDIVO® (Nivolumab) And IMBRUVICA®(Ibrutinib) In Non-Hodgkin Lymphoma 10/13/2014 8:44:15 AM
Janssen Research & Development Demonstrates Continued Commitment To Combating Hepatitis C In European Patients With Data Presented At Viral Hepatitis Congress 10/10/2014 8:07:19 AM